Teijin Medical Technologies Co., Ltd.
https://teijin-medical.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teijin Medical Technologies Co., Ltd.
MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
Global Medtech Recovers Core Growth After A Year Like No Other
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies.
Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
New $90M Medtech Convergence Fund Will Focus On Home Technologies
SV Health Investors has launched a new $90m venture fund to develop early-stage medtech start-ups. The fund has received investment from Japanese technology group Tejin.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Teijin Nakashima Medical Co. Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice